MIRA Pharmaceuticals Launches Groundbreaking Ketamir-2 Trial
MIRA Pharmaceuticals, Inc. has received approval from the Israeli Ministry of Health and the Institutional Review Board to embark on a Phase 1 clinical trial for Ketamir-2, a novel oral analog of ketamine targeting neuropathic pain management. The recent endorsement marks a significant milestone in the company’s endeavor to advance pain management solutions.
The approval follows MIRA's submission of an Investigational New Drug (IND) application designated for human trials. This step showcases the company's commitment to developing innovative therapies in the space of pain relief, which is a growing market due to rising incidences of chronic pain conditions.
Importance of Ketamir-2 in Pain Management
Ketamir-2, as revealed by preclinical research, exhibits superior efficacy and safety profiles compared to traditional options. Such findings have set the stage for its progression into human trials, with a focus on assessing its safety and tolerability in healthy adult volunteers.
Trial Structure and Objectives
The Phase 1 study will take place at the Clinical Pharmacology Unit in a prominent hospital. The trial comprises two components: a Single Ascending Dose (SAD) involving 32 participants, and a Multiple Ascending Dose (MAD) study with 24 participants. By evaluating both pharmacokinetics and any behavioral side effects associated with ketamine, researchers aim to establish a robust safety profile for Ketamir-2.
Trial Objectives and Timeline
The objectives include monitoring adverse events alongside serious adverse events during the study period. Beginning participant recruitment in the early part of the next year, MIRA plans to conclude Phase 1 by the last quarter of 2025. This timeline anticipates a seamless transition to the Phase 2a study, offered to individuals living with neuropathic pain.
Broader Implications Beyond Neuropathic Pain
MIRA Pharmaceuticals is not solely focusing on neuropathic pain; it is also expanding the scope of Ketamir-2 to potentially treat post-traumatic stress disorder (PTSD) and exploring topical formulations for localized pain relief. These extensions may substantially enhance Ketamir-2's clinical and market prospects.
The Growing Market for Neuropathic Pain Treatments
Neuropathic pain presents a rapidly expanding market, anticipated to reach a staggering $5.2 billion in North America alone by the close of the decade. This underscores a critical need for effective treatment options, which MIRA hopes to fulfill with its innovative Ketamir-2.
Company’s Broader Research Initiatives
In conjunction with Ketamir-2, MIRA is investigating Mira-55, which is aimed at memory enhancement. Such endeavors reflect MIRA Pharmaceuticals' commitment to addressing a spectrum of conditions affecting patient quality of life.
Recent Price Activity and Market Position
Recently, MIRA Pharmaceuticals saw its stock increase by 7.52%, trading at approximately $0.98 in premarket sessions. This positive market reception indicates investor optimism surrounding the company’s pipeline and strategic direction.
Frequently Asked Questions
What is Ketamir-2?
Ketamir-2 is a novel oral ketamine analog developed by MIRA Pharmaceuticals for treating neuropathic pain.
Where will the Ketamir-2 trials be conducted?
The trials will be held at the Clinical Pharmacology Unit, Hadassah Medical Center in Jerusalem, Israel.
What are the key objectives of the Phase 1 study?
The study aims to evaluate the safety, tolerability, and pharmacokinetics of Ketamir-2 in healthy adult volunteers.
When is participant recruitment scheduled to begin?
Subject recruitment for the trials is set to commence in the first quarter of the next year.
What other conditions is MIRA Pharmaceuticals exploring with Ketamir-2?
Besides neuropathic pain, the company is looking into Ketamir-2's efficacy for PTSD and localized pain relief formulations.
